Imaging Depression in Parkinson's Disease

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT06402955
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • 11C-UCB-J — RADIATION
    Radiotracer for imaging
  • ketamine hydrochloride — DRUG
    There will be a small subset (opt-in) who will receive a single dose of ketamine to determine the ability of ketamine to target these mechanisms and initiate an associated antidepressant response. If the participant is opting into the ketamine arm, the investigators will ask them to come in for one single-dose of ketamine and complete another PET and MRI scan post-ketamine treatment.

Study Details

The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.

Key Dates

Start date
Sep 1, 2024
Status verified
Mar 2026
Primary completion
Jan 1, 2029
Completion
Dec 1, 2029

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Parkinson's Disease with Major Depressive Disorder
    This study aims to identify mechanisms unique to patients with both Parkinson's Disease and Major Depressive Disorder.

Primary Outcome Measure

Montgomery-Åsberg Depression Rating Scale (MADRS) [ Time Frame: One day ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Yale UniversityNew HavenConnecticut06520
Sophie Holmes, PhD
[email protected]
203-685-4066

Find similar trials in New Haven, CT

By condition
DepressionParkinson's disease
By specialty
PsychiatryMental healthBehavioral healthNeurologyBrain disorders
By research site
Yale University· New Haven, CT

Related Studies